Connect with us

Artificial Intelligence

Bristol Myers Squibb buys Nvidia AI system for drug discovery

Published

on

Bristol Myers Squibb Nvidia AI

Bristol Myers Squibb invests in Nvidia’s latest AI supercomputer for drug discovery

Bristol Myers Squibb (BMS) is purchasing an Nvidia DGX SuperPOD powered by the chipmaker’s Vera Rubin architecture. The move marks the first time a life sciences company has acquired this specific system, designed to supercharge artificial intelligence across drug discovery and development.

The pharmaceutical giant said the new cluster will consist of eight DGX Vera Rubin NVL72 systems, each combining Nvidia Vera central processing units with Rubin graphics processing units. Financial terms were not disclosed.

Expanding computing capacity for research

BMS will use the infrastructure to train proprietary models and run predictions across its research programs. The system will handle work involving compounds, proteins, and other scientific data. This purchase expands BMS’s existing Nvidia infrastructure, which includes an older SuperPOD that company executives described as two or three generations behind Vera Rubin.

BMS has operated its current DGX SuperPOD for about three years. The company plans to combine it with the Vera Rubin system in a shared computing environment accessible from its research sites worldwide. The SuperPOD software stack can schedule training, prediction, and development workloads across the infrastructure. BMS said the expanded environment will give more scientists direct access to its computing resources.

Greg Meyers, BMS’s chief digital and technology officer, said computing requirements have increased as the company deploys larger AI models across its research organization. Erin Davis, vice president of research business insights and technology at BMS, said the existing infrastructure is operating at capacity. She attributed the demand to large-scale predictions involving large molecules and the development of internal foundation models.

Davis said the new system will not be limited to a small group of computational researchers. BMS plans to make it available across the research organization without the waiting periods and access limits associated with its current infrastructure.

Applying AI in drug discovery

BMS said AI informs the design of every small-molecule program and the majority of its large-molecule programs. The technology is applied to target identification, lead optimization, large-molecule predictions, and internal model development. The company said AI-enabled target identification has reduced some manual research work by several weeks. Large-molecule prediction workloads are also contributing to demand for additional graphics processing capacity.

Robert Plenge, BMS’s chief research officer, said the new system will allow scientists to evaluate more potential drug candidates during the early stages of development. “Maybe before we could do 10 and now we can do dozens,” Plenge said.

Computational screening allows researchers to assess potential compounds before selecting a smaller group for synthesis and laboratory testing. BMS applies this approach through a method it calls “Predict First,” which uses model-generated predictions to exclude molecules that do not meet the required properties before candidates are selected for synthesis.

Payal Sheth, senior vice president of therapeutic discovery sciences at BMS, said researchers use the predictions to identify molecules with the required combination of properties. “We use predictions as a way to prioritise synthesis of molecules with multi parameter optimisation,” Sheth said. “This ensures precious laboratory experiments are aligned with progressing molecules that have the highest probability of success.”

The method narrows the number of compounds sent for laboratory testing, allowing researchers to focus experiments on molecules that meet a program’s predicted requirements.

AI accelerates CELMoD compound development

BMS has also used AI to expand its library of CELMoD compounds, which are engineered to selectively degrade cancer-causing proteins. The company is studying the compounds in blood cancers and other diseases. BMS said the modeling work helped researchers examine additional protein targets and potential compounds before deciding which candidates to pursue experimentally.

The company is also using AI tools to shorten the time required to produce medicines for clinical trials. Plenge said the process has already been reduced by between 20% and 30% and could reach 50% in the coming years. He cited an experimental sickle cell disease treatment in early clinical development as one example of AI-supported research. Plenge said the treatment probably would not have been discovered without the company’s AI tools.

The figures refer to the time required to identify and produce candidates for clinical testing rather than their subsequent performance in trials.

BioNeMo toolkit enhances research capabilities

The Vera Rubin system will also give researchers access to Nvidia’s BioNeMo Agent Toolkit for biological and drug-discovery applications. BioNeMo provides tools for protein-structure prediction, molecular generation, molecular docking, sequence analysis, and genomics. It can also connect several computational tools within the same research workflow. BMS executives said human researchers will continue to review model outputs and decide which compounds or programs should advance.

Connecting research sites with unified infrastructure

BMS is introducing tools intended to reduce the specialist knowledge required to initiate complex computing tasks. The company said researchers will be able to start some prediction requests using natural-language instructions. The environment will be managed through Nvidia Mission Control, whose functions include cluster provisioning, infrastructure monitoring, and workload management, according to BMS.

The unified infrastructure will allow data and model outputs generated at one site to be used by teams elsewhere. BMS said datasets from a program in Lawrenceville, New Jersey, for example, can be incorporated into models used by researchers in San Diego. Sheth said the shared environment is intended to retain information from experiments and research programs across the organization.

“The compute infrastructure is what connects all of our scientists together and ensures that our learnings are institutionalised,” Sheth said.

The two SuperPODs will operate through a common data environment, allowing teams at different sites to access shared datasets and model outputs. BMS said the environment will include information from experiments, clinical readouts, and research partnerships. The company plans to allocate the new computing capacity across small- and large-molecule design, clinical research, and digital-twin applications. BMS did not provide details about the planned digital-twin work or the amount of capacity assigned to each area.

Performance gains and energy efficiency

Meyers said the Vera Rubin system will provide more computing capacity relative to its electricity use. BMS and Nvidia said the eight-system cluster will deliver up to 10 times the performance per megawatt of the infrastructure it replaces. “When you host these things, you have to pay an electric bill,” Meyers said. “Think of it as 10 times more compute capacity per watt spent … Electricity is not getting cheaper.”

BMS did not provide a specific deployment date or identify where the new system will be hosted.

For more on how AI is transforming the pharmaceutical industry, see AI-powered drug discovery trends and Nvidia’s role in healthcare AI.

Continue Reading

Artificial Intelligence

XDOF, three months out of stealth, is already closing in on a $1.2B Series B

Published

on

XDOF Series B

From stealth to unicorn talk in record time

Three months. That’s how long XDOF has been out in the open. And already, the robotics data startup is in late-stage conversations to raise a Series B at a valuation hovering around $1.2 billion, according to multiple sources familiar with the negotiations. The round would be led by 8VC.

Not bad for a company that didn’t even exist publicly until June.

XDOF was co-founded in 2024 by UC Berkeley researchers Philipp Wu (CEO) and Fred Shentu (CTO). Their origin story traces back to a research project called GELLO — a low-cost teleoperation system that lets a human operator control a robotic arm from a distance. The goal? Generate training data for robots. That work produced an influential paper in robotics and, eventually, a company.

The startup’s Series A, a $70 million round announced in June, drew participation from Thrive Capital, Andreessen Horowitz, Lux, and Spark Capital. At the time, XDOF wasn’t planning to raise again so soon. But the market had other ideas.

Why investors are knocking on XDOF’s door

The reason for the sudden interest? Growth. Real, measurable growth.

XDOF’s annualized revenue is approaching $50 million, sources say. That kind of traction, so soon after a Series A, tends to make venture capitalists sit up and take notice. It also tends to make them pick up the phone.

“They weren’t out raising,” one person familiar with the situation told TechCrunch. “The VCs came to them.”

Terms aren’t final, and the total capital being raised remains unclear. TechCrunch couldn’t confirm whether the $1.2 billion valuation includes the new funding or sits on top of it. Both XDOF and 8VC declined to comment.

The Scale AI for physical robots

XDOF’s pitch is straightforward: it builds the data pipelines, collection tools, and annotation systems that frontier AI labs and robotics companies would rather not build themselves. Think of it as an outsourced data-supply chain for the robotics industry.

Investors describe XDOF as the Scale AI or Mercor of physical robotics — a nod to the data-labeling giants that powered the AI boom. The comparison makes sense. Large language models trained on the entire internet. Physical robots? They don’t have that luxury. There’s no massive, ready-made dataset of real-world robot interactions sitting online. That scarcity makes data collection the critical bottleneck on the road to general-purpose machines.

Wu felt that bottleneck firsthand as a PhD student. His research on how robots learn from large datasets kept hitting the same wall: “large-scale data to work with” simply didn’t exist, he told TechCrunch in June.

Building the ABC dataset

XDOF is tackling that problem head-on. The startup is partnering with UC Berkeley’s AI Research lab to release what it believes is the largest collection of high-quality robot training data ever assembled. The dataset is called ABC.

Collecting that data requires a hybrid approach. XDOF combines remote robot teleoperation with human collectors who wear sensors to record everyday tasks. Think folding clothes. Flattening boxes. The mundane, physical chores that robots still struggle to master.

The company plans to hire and train teams of data collectors around the world. Two main roles are emerging:

  • Teleoperators who steer robots remotely to demonstrate tasks
  • Egocentric operators who wear body sensors to capture natural movement data

Early traction and the competitive landscape

XDOF has already signed up 20 customers, including several frontier AI labs, according to previous statements to TechCrunch. That customer base, combined with the revenue trajectory, helps explain the valuation chatter.

But XDOF isn’t alone in this niche. Other startups chasing real-world data for robot training include Mecka AI. And the human-data platforms that started with LLMs — like Scale AI and Micro1 — are expanding beyond text and images into physical domains.

The race to build the data infrastructure for physical AI is heating up. Whoever wins it will effectively control the fuel supply for the next generation of robots. That’s a position worth paying up for.

Whether the $1.2 billion valuation holds remains to be seen. Deals at this stage can shift. But the fact that XDOF is even in this conversation — three months after emerging from stealth — says something about the demand for what it’s building.

For more on how data is shaping the future of AI, check out AI data labeling trends and robotics funding rounds in 2024.

Continue Reading

Artificial Intelligence

New York City Pulls AI From Younger Classrooms—Here’s Why It Matters

Published

on

NYC AI ban

New York City Just Hit Pause on AI in Classrooms

New York City Public Schools is drawing a hard line: no generative AI for students from 2-K through eighth grade during the 2026-2027 school year. That’s over half a million kids walking into classrooms next week without access to AI-powered tools.

The district says it will remove software with student-facing AI features and block AI companion chatbots. High schoolers? They’re exempt. This isn’t a blanket ban—it’s a targeted move to decide when kids should actually start using the technology.

Mayor Zohran Mamdani put it bluntly: “The tech industry wants us to believe that AI-powered early education is not only inevitable, but necessary. We do not see it that way.”

Why NYC Is Worried About AI for Younger Students

The fear isn’t just that a kid will ask ChatGPT to write an essay. City officials want younger students to build core skills—critical thinking, creativity, communication—without leaning on AI as a crutch. They’re also pushing for stronger human connections in classrooms, not another screen.

Schools Chancellor Kamar Samuels said the city refuses to assume that innovation automatically equals more technology in front of students. It’s a deliberate slowdown, and it follows last year’s bell-to-bell cellphone ban that already limits device use during school hours.

What Happens When Kids Reach High School?

AI doesn’t vanish once students hit ninth grade. Instead, the district plans to roll out AI literacy classes twice a year. The goal? Teach teenagers how to think critically about the technology before they become dependent on it.

That’s a different approach from just saying no. It’s about timing—letting younger minds develop without AI, then giving older students the tools to question it.

The National Battle Over AI in Education

NYC’s decision sits at the center of a much bigger fight. The White House has pushed educators to embrace AI responsibly. Some teachers already use it to craft lesson plans, give feedback, or break down tough subjects. But not everyone’s on board.

The Department of Health and Human Services recently gathered childhood experts to talk about excessive screen time. Officials have also called for tougher safeguards around social media and AI. The message? Kids are spending too much time in front of screens, and AI might make it worse.

A Bold Experiment With Zero AI

Here’s what makes NYC’s move so interesting: instead of asking how much AI younger students should use, the largest school district in the country is starting with none. For one academic year, they’re testing whether classrooms are better off with AI kept outside the door.

That’s a radical stance, and it’s not without critics. Some educators argue AI can personalize learning or help struggling students catch up. But NYC is betting that a year without AI will reveal what kids actually need—not what tech companies think they need.

What This Means for Parents and Teachers

If you’re a parent in NYC, expect changes. AI-based apps may disappear from your child’s school day. Teachers will need to plan lessons without generative AI tools. And students in grades 2-K through 8 will rely more on traditional methods—paper, pencils, and human interaction.

For teachers elsewhere, this could be a signal. NYC is the biggest district to take this stance, and its findings could shape policies nationwide. The next year will be watched closely by educators, policymakers, and tech giants alike.

What Happens Next?

The district will spend the year studying how generative AI affects students before deciding what comes next. That research could lead to a permanent ban, a partial rollout, or something entirely different.

For now, NYC is making a statement: childhood shouldn’t be an AI beta test. Whether that’s the right call or a step backward, we’ll know more in 2027. Until then, the debate over AI in schools just got a lot more interesting.

If you’re curious about how AI is shaping other areas, check out our take on AI in education trends or classroom technology policies.

Continue Reading

Artificial Intelligence

Meta’s Muse Spark 1.3 takes on GPT-5.6 and Claude — but can it really win?

Published

on

Muse Spark 1.3

Meta just fired a serious shot in the AI arms race

The company quietly unleashed Muse Spark 1.3, its most advanced AI model to date, and it’s aiming straight at the top dogs. Developers can already access and pay for the update, which Meta says represents a massive leap forward in performance.

It won’t stay confined to the developer sandbox for long. Over the coming weeks, the model will roll out across Instagram, Facebook, and the Meta AI assistant — putting it in front of billions of everyday users.

What makes Muse Spark 1.3 actually different?

Meta’s Chief AI Officer, Alexandr Wang, didn’t mince words. He called this “the biggest jump so far on model performance,” pointing to serious gains in two areas: coding and agentic tasks — the kind where the AI acts on your behalf rather than just answering questions.

But here’s the catch. Wang told Bloomberg that Muse Spark 1.3 is competitive with Anthropic’s Claude Fable 5.1 and even beats OpenAI’s GPT-5.6 Sol at coding. That’s a bold claim, especially with OpenAI’s upcoming Astra model lurking in the wings.

Take those comparisons with a grain of salt, though. Benchmarks can be gamed, and a model that crushes one test might stumble on a totally different task. Real-world performance is what actually matters.

Efficiency gains under the hood

Wang broke down a few upgrades that set Muse Spark 1.3 apart:

  • 25% fewer tokens needed to complete the same job — meaning lower costs and faster responses
  • Multi-workflow handling — it can juggle several tasks at once instead of forcing separate sessions
  • Better context retention across long, complicated instructions
  • Self-awareness of limits — the model now pauses to ask for clarification before taking any irreversible action

That last point is quietly important. AI that knows when it doesn’t know is a big step toward trustworthiness, especially for agentic use cases.

Pricing stays flat, adoption explodes

Here’s something developers will appreciate: Meta isn’t raising prices. Muse Spark 1.3 costs the same as its predecessor, Muse Spark 1.2. That’s a smart move when rivals are hiking rates.

Wang told Bloomberg that adoption on Meta’s developer platform has been strong — some users are burning through trillions of tokens every week. Those numbers suggest real usage, not just hype.

What about open-source fans? Meta hasn’t decided whether it will release the model’s weights — the blueprint that lets outside developers build on top of it. The older Muse Spark 1.2 weights are still headed for release, but the new model’s future remains unclear.

The bigger picture: Meta’s spending spree continues

Meta is still pouring billions into AI infrastructure, and Muse Spark 1.3 is the clearest signal yet that the company believes it’s closing the gap with OpenAI and Anthropic. Whether that’s true or just corporate bravado will play out in the benchmarks and real-world deployments over the coming months.

For now, the model is available to developers, and the app rollout is imminent. If you’re building on Meta AI tools, this update is worth a serious look. And if you’re just a curious user, you’ll likely meet Muse Spark 1.3 in your Instagram feed sooner than you think.

One thing’s certain: the AI race just got a lot more interesting.

Continue Reading

Trending